FDA — authorised 17 July 2023
- Application: BLA761328
- Marketing authorisation holder: ASTRAZENECA AB
- Local brand name: BEYFORTUS
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 BEYFORTUS in United States
FDA authorised BEYFORTUS on 17 July 2023
Marketing authorisations
FDA
- Status: approved
BEYFORTUS in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is BEYFORTUS approved in United States?
Yes. FDA authorised it on 17 July 2023; FDA has authorised it.
Who is the marketing authorisation holder for BEYFORTUS in United States?
ASTRAZENECA AB holds the US marketing authorisation.